|Articles|June 10, 2015
- Precision Medicine
- Volume 2
- Issue 1
Significance of the NCI Molecular Analysis for Therapy Choice Program
Author(s)Jonathan C. Trent, MD, PhD
Jonathan C. Trent, MD, PhD, professor of medicine, co-director, Musculoskeletal Center, Sarcoma Medical Research Program, Sylvester Comprehensive Cancer Center, University of Miami Health System, gives an overview of the NCI Molecular Analysis for Therapy Choice Program (MATCH).
Advertisement
Jonathan C. Trent, MD, PhD, professor of medicine, co-director, Musculoskeletal Center, Sarcoma Medical Research Program, Sylvester Comprehensive Cancer Center, University of Miami Health System, gives an overview of the NCI Molecular Analysis for Therapy Choice Program (MATCH).
<<<
Articles in this issue
about 11 years ago
Nivolumab and Future Biomarkers in NSCLCabout 11 years ago
Clinical Validation and Utility of a Liquid Biopsy in NSCLCabout 11 years ago
Scoring System May Help Guide Therapy in Triple-Negative Breast CancerAdvertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Long-Term OMNIVORE Data Show Durable Treatment-Free Survival in RCC
2
Phase 3 ENHANCE Trial: Magrolimab Adds Toxicity, Not Benefit, in MDS
3
On-Body Injector Technology Streamlines Subcutaneous Myeloma Therapy
4
De-Escalated Neoadjuvant HER2-Targeted Therapy Shows Durable 5-Year Survival
5